Detalhe da pesquisa
1.
How patients with multiple sclerosis acquire disability.
Brain
; 145(9): 3147-3161, 2022 09 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35104840
2.
Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Mult Scler
; 28(10): 1526-1540, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35261318
3.
Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation.
Mult Scler
; 27(13): 2062-2076, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-33507835
4.
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Mult Scler
; 27(10): 1564-1576, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33205682
5.
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
Eur J Neurol
; 28(12): 4135-4145, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34431170
6.
Advancing data science in drug development through an innovative computational framework for data sharing and statistical analysis.
BMC Med Res Methodol
; 21(1): 250, 2021 11 14.
Artigo
Inglês
| MEDLINE | ID: mdl-34773974
7.
Video-Based Pairwise Comparison: Enabling the Development of Automated Rating of Motor Dysfunction in Multiple Sclerosis.
Arch Phys Med Rehabil
; 101(2): 234-241, 2020 02.
Artigo
Inglês
| MEDLINE | ID: mdl-31473205
8.
Autoencoder as a New Method for Maintaining Data Privacy While Analyzing Videos of Patients With Motor Dysfunction: Proof-of-Concept Study.
J Med Internet Res
; 22(5): e16669, 2020 05 08.
Artigo
Inglês
| MEDLINE | ID: mdl-32191621
9.
A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.
J Med Internet Res
; 22(2): e16932, 2020 02 12.
Artigo
Inglês
| MEDLINE | ID: mdl-32049062
10.
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
Lancet
; 391(10127): 1263-1273, 2018 03 31.
Artigo
Inglês
| MEDLINE | ID: mdl-29576505
11.
Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.
Mult Scler
; 25(12): 1673-1681, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30168739
12.
Neurostatus e-Scoring improves consistency of Expanded Disability Status Scale assessments: A proof of concept study.
Mult Scler
; 23(4): 597-603, 2017 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-27364325
13.
Rationale for Use of Sphingosine-1-Phosphate Receptor Modulators in COVID-19 Patients: Overview of Scientific Evidence.
J Interferon Cytokine Res
; 43(6): 246-256, 2023 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-36454249
14.
Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis.
Int J MS Care
; 25(5): 226-232, 2023.
Artigo
Inglês
| MEDLINE | ID: mdl-37720262
15.
Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Neurology
; 98(21): e2120-e2131, 2022 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35379762
16.
Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.
Int J MS Care
; 24(5): 230-234, 2022.
Artigo
Inglês
| MEDLINE | ID: mdl-36090237
17.
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
J Neurol
; 269(9): 5093-5104, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35639197
18.
Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Curr Med Res Opin
; 37(11): 1933-1944, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34384311
19.
Siponimod and Cognition in Secondary Progressive Multiple Sclerosis: EXPAND Secondary Analyses.
Neurology
; 96(3): e376-e386, 2021 01 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33328324
20.
The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis.
Curr Med Res Opin
; 36(7): 1145-1156, 2020 07.
Artigo
Inglês
| MEDLINE | ID: mdl-32216597